
CLAIMS

1. A combination of at least one sigma ligand and at least one chemotherapeutic drug for simultaneous, separate or sequential administration, wherein the sigma ligand has the general formula (I):



(I)

wherein

R_1 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_3 and R_4 are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic

heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, -CN, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together they form a optionally substituted fused ring system;

R_5 and R_6 are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, -CN, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted heterocyclyl group;

n is selected from 1, 2, 3, 4, 5, 6, 7 and 8;

t is 1,2 or 3;

R_8 and R_9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen;

or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

2. A combination according to claim 1, wherein R_1 is selected from H, $-COR_8$ and substituted or unsubstituted alkyl.
3. A combination according to claims 1 or 2, wherein R_2 is H or alkyl.
4. A combination according to any preceding claims, wherein R_3 and R_4 together form a fused naphthyl ring system.
5. A combination according to any preceding claims, wherein R_5 and R_6 together form a morpholine-4-yl group.
6. A combination according to any preceding claims, wherein the sigma ligand of formula (I) is 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

7. A combination according to any preceding claims, wherein the sigma ligand of formula (I) is 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride.

8. A combination according to any preceding claims, wherein the chemotherapeutic drug is selected from the group formed by taxanes, vinca alkaloids, drugs derived from platinum, bortezomib or thalidomide and its derivatives.

9. A combination according to any preceding claims, wherein the chemotherapeutic drug is selected from the group formed by paclitaxel, oxaliplatin, cisplatin, vincristine, bortezomib, thalidomide or lenolidamide.

10. A combination according to any preceding claims, wherein the combination comprises 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine and a chemotherapeutic drug selected from paclitaxel, oxaliplatin or cisplatin.

11. A combination as defined in any of claims 1 to 10 for its use in the manufacture of a medicament.

12. A combination as defined in any of claims 1 to 10 for its use in the prevention or treatment of pain induced by chemotherapy.

13. A combination according to claim 12, wherein the pain is selected from peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis and neuropathy.

14. A compound of formula (I) as defined in any of claims 1 to 7, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, for its use in the treatment or prevention of pain induced by chemotherapy.

15. A compound according to claim 14, for its use in the treatment or prevention of pain induced by a chemotherapeutic drug selected from taxane, vinca alkaloid, platinum derivatives, bortezomib or thalidomide and its derivatives.

16. A compound according to claim 14, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, for its use in the prevention of pain induced by chemotherapy.

17. A compound according to claims 14, 15 or 16, wherein the pain is selected from peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis and neuropathy.


18. Use of a compound of formula (I) as defined in any of claims 1 to 7, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, in the

manufacture of a medicament for the treatment or prevention of pain induced by chemotherapy.

19. Use of a sigma ligand of formula (I) as defined in any of claims 1-7 in the manufacture of a medicament for treatment of a patient suffering from pain induced by chemotherapy, or likely to suffer pain as a result of a chemotherapeutic treatment.

CLAIMS

1. A combination of at least one sigma ligand and at least one chemotherapeutic drug for simultaneous, separate or sequential administration, wherein the sigma ligand has the general formula (I):



(I)

wherein

R_1 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen;

R_3 and R_4 are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic

heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, -CN, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together they form a optionally substituted fused ring system;

R_5 and **R_6** are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, -CN, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, and halogen, or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted heterocyclyl group;

n is selected from 1, 2, 3, 4, 5, 6, 7 and 8;

t is 1,2 or 3;

R_8 and **R_9** are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen;

or a pharmaceutically acceptable salt, isomer or solvate thereof; and

the chemotherapeutic drug is selected from the group formed by taxanes, vinca alkaloids, drugs derived from platinum and thalidomide.

2. A combination according to claim 1, wherein R_1 is selected from H, $-COR_8$ and substituted or unsubstituted alkyl.

3. A combination according to claims 1 or 2, wherein R_2 is H or alkyl.

4. A combination according to any preceding claims, wherein R_3 and R_4 together form a fused naphthyl ring system.

5. A combination according to any preceding claims, wherein R_5 and R_6 together form a morpholine-4-yl group.

6. A combination according to any preceding claims, wherein the sigma ligand of formula (I) is 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine, or a pharmaceutically acceptable salt, isomer or solvate thereof.

7. A combination according to any preceding claims, wherein the sigma ligand of formula (I) is 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride.

8. A combination according to any preceding claims, wherein the chemotherapeutic drug is selected from the group formed by paclitaxel, oxaliplatin, cisplatin, vincristine, and thalidomide.

9. A combination according to any preceding claims, wherein the combination comprises 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine and a chemotherapeutic drug selected from paclitaxel, oxaliplatin or cisplatin.

10. A combination as defined in any of claims 1 to 9 for its use in the manufacture of a medicament.

11. A combination as defined in any of claims 1 to 9 for its use in the prevention or treatment of pain induced by chemotherapy.

12. A combination according to claim 11, wherein the pain is selected from peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis and neuropathy.

13. A compound of formula (I) as defined in any of claims 1 to 7, or a pharmaceutically acceptable salt, isomer or solvate thereof, for its use in the treatment or prevention of pain induced by chemotherapy, wherein the chemotherapeutic drug is selected from the group formed by taxanes, vinca alkaloids, drugs derived from platinum and thalidomide.

14. A compound according to claim 13, or a pharmaceutically acceptable salt, isomer or solvate thereof, for its use in the prevention of pain induced by chemotherapy, wherein the chemotherapeutic drug is selected from the group formed by taxanes, vinca alkaloids, drugs derived from platinum and thalidomide.

15. A compound according to claims 13 or 14, wherein the pain is selected from peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis and neuropathy.